Table 1.
Baseline demographic and clinical characteristics of patients stratified by patterns of progression (n = 118)
| Characteristics | No. patients (%) | |||
| Total (n = 118) |
Oligoprogression
(n = 46) |
Systemic progression
(n = 72) |
P -value | |
| Median age, year (range) | 62 (36-80) | 63.5 (46-77) | 60.5 (36-80) | 0.250 |
| Gender | 0.059 | |||
| Male | 95 (80.5) | 41 (89.1) | 54 (75.0) | |
| Female | 23 (19.5) | 5 (10.9) | 18 (25.0) | |
| ECOG PS | 0.048 | |||
| 0-1 | 107 (90.7) | 45 (97.8) | 62 (86.1) | |
| 2 | 11 (9.3) | 1 (2.2) | 10 (13.9) | |
| Smoking history | 0.001 | |||
| Current/Former | 71 (60.2) | 36 (78.3) | 35 (48.6) | |
| Never | 47 (39.8) | 10 (21.7) | 37 (51.4) | |
| Histology | 0.602 | |||
| Non-squamous | 74 (62.7) | 27 (58.7) | 47 (65.3) | |
| Squamous | 37 (31.4) | 17 (37.0) | 20 (27.8) | |
| NOS | 7 (5.9) | 2 (4.3) | 5 (6.9) | |
| PD-L1 status | 0.848 | |||
| ≥ 1% | 23 (19.5) | 9 (19.6) | 14 (19.4) | |
| < 1% | 13 (11.0) | 6 (13.0) | 7 (9.7) | |
| Not examined | 82 (69.5) | 31 (67.4) | 51 (70.9) | |
| Lines of therapy | 0.936 | |||
| 1 | 35 (29.7) | 14 (30.4) | 21 (29.2) | |
| 2 | 50 (42.4) | 20 (43.5) | 30 (41.6) | |
| ≥ 3 | 33 (27.9) | 12 (26.1) | 21 (29.2) | |
| Number of metastatic sites | ||||
| Mean (SD) | 1.5 (1.2) | 1.3 (1.1) | 1.7 (1.2) | 0.075 |
| Treatment strategy | 0.973 | |||
| ICIs monotherapy | 68 (57.6) | 26 (56.5) | 42 (58.3) | |
| ICIs + chemotherapy | 37 (31.4) | 15 (32.6) | 22 (30.6) | |
| ICIs + anti-angiogenesis | 13 (11.0) | 5 (10.9) | 8 (11.1) | |
| Best response to treatment | 0.117 | |||
| PR | 29 (24.6) | 15 (32.6) | 14 (19.4) | |
| SD | 61 (51.7) | 24 (52.2) | 37 (51.4) | |
| PD | 28 (23.7) | 7 (15.2) | 21 (29.2) | |
| ORR (%) | 24.6 | 32.6 | 19.4 | 0.105 |
| DCR (%) | 76.3 | 84.8 | 70.8 | 0.082 |
| Median PFS (months) | 5.70 | 5.17 | 0.491 | |
| First-line | 8.60 | 8.64 | 8.43 | 0.755 |
| Second-line and beyond | 4.40 | 4.98 | 4.37 | 0.293 |
ECOG PS: Eastern Cooperative Oncology Group performance status; NOS: not otherwise specified; PD-L1: programmed cell death ligand 1; ICIs: immune checkpoint inhibitors; PR: partial response; SD: stable disease; PD: progressive disease; ORR: objective response rate; DCR: disease control rate; PFS: progression-free survival.